Journal article
Deriving Optimal Treatment Timing for Adaptive Therapy: Matching the Model to the Tumor Dynamics
- Alternative title:
- Deriving Optimal Treatment Timing for Adaptive Therapy:..
- Abstract:
- Adaptive therapy (AT) protocols have been introduced to combat drug resistance in cancer, and are characterized by breaks from maximum tolerated dose treatment (the current standard of care in most clinical settings). These breaks are scheduled to maintain tolerably high levels of tumor burden, employing competitive suppression of treatment-resistant sub-populations by treatment-sensitive sub-populations. AT has been integrated into several ongoing or planned clinical trials, including treatment of metastatic castrate-resistant prostate cancer, ovarian cancer, and BRAF-mutant melanoma, with initial clinical results suggesting that it can offer significant extensions in the time to progression over the standard of care. Prior AT protocols apply drug treatment when the tumor is within a specific size window, typically determined by the initial tumor size. However, this approach may be sub-optimal as it does not account for variation in tumor dynamics between patients, resulting in significant heterogeneity in patient outcomes. Mathematical modeling and analysis have been proposed to optimize adaptive protocols, but they do not account for clinical restrictions, most notably the discrete time intervals between the clinical appointments where a patient’s tumor burden is measured and their treatment schedule is re-evaluated. We present a general framework for deriving optimal treatment protocols that account for these discrete time intervals, and derive optimal schedules for several models to avoid model-specific personalization. We identify a trade-off between the frequency of patient monitoring and the time to progression attainable, and propose an AT protocol that determines drug dosing based on a patient-specific threshold for tumor size. Finally, we identify a subset of patients with qualitatively different dynamics that instead require a novel AT protocol based on a threshold that changes over the course of treatment.
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Version of record, pdf, 1.1MB, Terms of use)
-
(Preview, Other, pdf, 593.7KB, Terms of use)
-
- Publisher copy:
- 10.1007/s11538-025-01525-y
Authors
+ Engineering and Physical Sciences Research Council
More from this funder
- Funder identifier:
- https://ror.org/0439y7842
- Publisher:
- Springer
- Journal:
- Bulletin of Mathematical Biology More from this journal
- Volume:
- 87
- Issue:
- 10
- Pages:
- 146
- Article number:
- 146
- Publication date:
- 2025-09-08
- Acceptance date:
- 2025-08-27
- DOI:
- EISSN:
-
1522-9602
- ISSN:
-
0092-8240
- Language:
-
English
- Keywords:
- Pubs id:
-
2287712
- UUID:
-
uuid_36851f18-22f8-49bc-995b-fcaedbce14dd
- Local pid:
-
pubs:2287712
- Source identifiers:
-
3271043
- Deposit date:
-
2025-09-09
- ARK identifier:
This ORA record was generated from metadata provided by an external service. It has not been edited by the ORA Team.
Terms of use
- Copyright date:
- 2025
- Licence:
- CC Attribution (CC BY)
If you are the owner of this record, you can report an update to it here: Report update to this record